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Background
Human induced pluripotent stem cells (huiPS) are pro-
duced by in vitro reprogrammation of somatic cells. They
offer new perspectives in cell therapy due to their ability
to differentiate in any cell types. Nevertheless, used either
in allotransplantation (different donor and recipient), or in
autologous tranplantation (patient’s derived iPS), iPS
derived cells can induce rejecting immune responses [1]. It
appears, therefore, crucial to better characterize their
immunogenicity.
Methods
Applying to human iPS cells an in vitro ectodermal differ-
entiation protocol (cellular matrix and BMP4 treatment)–
initially designed in the laboratory for embryonic stem
cells [2] - we isolated a cell population that can serve to
analyse immunogenicity of iPS-derived cells.
Results
We demonstrate that these cells are unable to directely
activate human lymphocytes, but instead display an
immunosuppressive activity on allogenic activated T
lymphocytes as shown by a strong inhibition of allogenic
CD4- and CD8-positive T cell proliferation and reduc-
tion in IL-2 and IFN-gamma production. While immu-
nossupressive soluble factors such as IL-10 or TGF-beta
are not involved, we demonstrate, with the use of block-
ing antibodies, that this immunosuppressive activity rely
on the inhibitory interaction between the PD1 receptor
(upregulated on T cells) and its ligand PD-1L strongly
expressed by our human iPS –derived population.
Finally, we demonstrate that this cell population contains
mesenchymal stem cells, as shown by immunophenotyping,
cytokines production and in vitro differentiation into adipo-
cytes, osteoblasts and chondrocytes.
Conclusions
These results suggest that during in vitro human iPS cell
differentiation into defined cell populations with strong
interest in cellular therapy, some mesenchymal stem cells
with immunosuppressive activity may differentiate and
limit the immune process suppose to induce their rejec-
tion. Interestingly, the mechanisms involved might in fine
participate in establishing a long term immune tolerance.
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